Analysis of the efficacy of lamb′s tripe extract and vitamin B12 capsule in the treatment of 240 cases of chronic atrophic gastritis
10.3760/cma.j.cn311367-20210705-00368
- VernacularTitle:羔羊胃提取物维B12胶囊治疗240例慢性萎缩性胃炎的疗效分析
- Author:
Luyao ZHANG
1
;
Jie LIU
;
Yan NIE
;
Jiangyi ZHU
;
Jun LIU
;
Yongquan SHI
Author Information
1. 空军军医大学西京医院消化内科 肿瘤生物学国家重点实验室 国家消化系统疾病临床医学研究中心 西安 710032
- Keywords:
Lamb′s tripe extract and vitamin B12 capsule;
Chronic atrophic gastritis;
Intestinal metaplasia;
Stomach neoplasms;
Malignancy risk
- From:
Chinese Journal of Digestion
2021;41(Z1):33-40
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the efficacy and related factors of lamb′s tripe extract and vitamin B12 capsule (LTEVB12) in the treatment of chronic atrophic gastritis.Methods:From October 1st 2016 to April 30th 2021, 240 patients with chronic atrophic gastritis visited the Department of Gastroenterology at Xijing Hospital, Air Force Medical University were retrospectively analyzed. All patients regularly took LTEVB12 (110 U/day, 3 times/day) for six months. At the end of treatment, endoscopy and gastric mucosal biopsy were conducted. The therapeutic effects were evaluated by comparing the changes of operative link on gastritis assessment (OLGA) and operative link on gastritis assessment based on intestinal metaplasia (OLGIM) staging before and after treatment. The related factors affecting the efficacy of the drug were analyzed. Multivariate logistic regression analysis was used for statistical analysis.Results:After half a year of treatment, the reversal efficiency of atrophy and intestinal metaplasia was 45.4% (109/240) and 37.9% (91/240), respectively, and the total efficiency was 62.9% (151/240). The reversal efficiency of OLGA and OLGIM staging reversed from high stage (stage Ⅲ to Ⅳ) to low stage (stage 0 to Ⅱ) was 53.4% (63/118) and 54.5% (36/66), respectively. The results of multivariate analysis showed that female, vitamin supplementation (≥3 times/week), negative or successful eradication of Helicobacter pylori and mild inflammatory status (inflammation score: 1 to 2) were associated with improving the efficacy of LTEVB12 (odds ratio=1.798, 3.730, 2.817 and 4.631, 95% confidence interval 1.055 to 3.064, 1.197 to 11.627, 1.171 to 6.779, 1.480 to 14.493; all P<0.05). High consumption of pickled food (≥3 times/week) was associated with reducing efficacy of LTEVB12 (odds ratio=0.384, 95%confidence interval 0.200 to 0.740). Conclusion:LTEVB12 has better reversal therapeutic effect on atrophy and intestinal metaplasia, and may reduce the risk of gastric cancer in patients with chronic atrophic gastritis.
